19.12.2013 15:03:32
|
Pre-market Movers For Dec 19 (FB, ACN, ALIM, PSDV, GRPN, VRTX)
(RTTNews) - Gainers:
Accenture plc (ACN) is gaining 4 percent to $78.58. The company's first quarter profit and revenues were higher than in the year-ago quarter. The company backed its fiscal 2014 net revenue growth guidance and raised its earnings per share forecast, reflecting its updated foreign-exchange assumption.
Alimera Sciences Inc. (ALIM) is surging 79 percent to $4.57 and pSivida Corp (PSDV) is up 51 percent to $4.50 based on the news that Alimera need not conduct any new clinical trials in connection with the FDA's review of Iluvien prior to approval. It has also been decided that the Advisory Committee meeting is no longer necessary.
Groupon, Inc. (GRPN) is up 3 percent to $11.65.
Decliners:
Facebook, Inc. (FB) is down nearly 3 percent to $54.10. The company announced that it is commencing public offering of 70.00 million shares of its Class A common stock. Of the total shares offered, 27 million shares are being offered by the company, and a total of 42.995 million shares are being offered by certain selling stockholders, including 41.35 million shares offered by Mark Zuckerberg.
Vertex Pharmaceuticals Inc. (VRTX) is falling 4 percent to $66.01. The company announced that Phase 3 study of ivacaftor in 69 people 6 years of age and older with cystic fibrosis who have the R117H mutation did not meet its primary endpoint of the absolute change from baseline in FEV1 throughout the treatment period for ivacaftor compared to placebo across all patients.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Accenture plcmehr Nachrichten
10.01.25 |
S&P 500-Titel Accenture-Aktie: So viel Verlust hätte ein Investment in Accenture von vor 3 Jahren eingebracht (finanzen.at) | |
07.01.25 |
Kion, Nvidia, Accenture mit KI-Lieferketten-Optimierung - Kion-Aktie +9% (Dow Jones) | |
03.01.25 |
S&P 500-Wert Accenture-Aktie: So viel Gewinn hätte eine Accenture-Investition von vor einem Jahr eingebracht (finanzen.at) | |
27.12.24 |
S&P 500-Titel Accenture-Aktie: So viel Gewinn hätte ein Investment in Accenture von vor 10 Jahren eingebracht (finanzen.at) | |
25.12.24 |
Generative KI: Warum der NVIDIA-CEO auf Accenture setzt (finanzen.at) | |
20.12.24 |
Freundlicher Handel: S&P 500 mit Kursplus (finanzen.at) | |
20.12.24 |
S&P 500-Titel Accenture-Aktie: So viel Gewinn hätte ein Accenture-Investment von vor 5 Jahren abgeworfen (finanzen.at) | |
19.12.24 |
NYSE-Handel S&P 500 fällt zum Ende des Donnerstagshandels zurück (finanzen.at) |
Analysen zu Accenture plcmehr Analysen
Aktien in diesem Artikel
Accenture plc | 340,25 | -0,61% | |
Meta Platforms (ex Facebook) | 592,50 | -0,17% | |
Vertex Pharmaceuticals Inc. | 402,45 | -0,64% |